AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Protopic.
(tacrolimus ointment 0.1%, 0.03%, Fujisawa Healthcare)
A topical formulation of an immunosuppressant drug for treating moderate to severe atopic dermatitis patients aged 2 years and older for whom the use of alternative, conventional therapies is considered inadvisable because of potential risks, and for those who do not have adequate responses to or are intolerant of alternative, conventional therapies. The first nonsteroidal topical immunomodulator approved.
* Dosage: For short-term and intermittent, long-term therapy Both concentrations approved for adults.
* Special Considerations: In studies, local irritation and skin burning were more common among people using Protopic; these symptoms lasted for a short period, occurred early in treatment, and rarely led to discontinuation. During treatment, patients should avoid unprotected exposure to sunlight, sun lamps, tanning beds, and UVA or UVB light treatments. Long-term safety issues that are not resolved are the uncertainty over whether treatment with a topical immunosuppressant drug increases the risk of lymphoma and non-melanoma skin cancers, known risks of systemic ...
- Montelukast treatment of moderate to severe atopic dermatitis in adults: a...
- Magazine article from: Journal of Drugs in Dermatology September 1, 2005 700+ words
...Montelukast Treatment of Moderate to Severe Atopic Dermatitis in Adults: A Randomized...montelukast in the treatment of moderate to severe atopic dermatitis. Fifty-nine patients...montelukast in the treatment of moderate to severe atopic dermatitis. Rationale for the use...
- Evaluation of the efficacy, safety and tolerability of tacrolimus ointment in...
- Magazine article from: Indian Journal of Dermatology, Venereology and Leprology Saple, D.G. Torsekar, R.G. Pawanarkar, Vikas Wali, Vijajkumar Ravichandran, G. Dhanalakshmi, U.R. Dongre, Neeles Ballary, Chetna Desai, Anish November 1, 2003 700+ words
...as a new treatment for moderate to severe atopic dermatitis. The present study was...diagnosed to be suffering from moderate to severe atopic dermatitis as per the Rajka and Langeland...in Indian patients of moderate to severe atopic dermatitis. KEY WORDS: Tacrolimus...
- Pharmacokinetics of tacrolimus following topical application of tacrolimus...
- Magazine article from: Journal of Drugs in Dermatology Krueger, Gerald G. Eichenfield, Lawrence Goodman, J. John Krafchik, Bernice R. Carlin, Christopher S. Pang, Mei-Lin Croy, Richard Holum, Mary Elizabeth Jaracz, Eileen Sawamoto, Taiji Keirns, James February 1, 2007 700+ words
...pediatric patients with moderate to severe atopic dermatitis from all clinical trials...accumulation in patients with moderate to severe atopic dermatitis and extensive disease...formulation for the treatment of moderate to severe atopic dermatitis (AD) and in oral and intravenous...
- Novartis: severe atopic dermatitis approved for Neoral.
- News wire article from: Chemical Business Newsbase November 3, 2008 700+ words
...immunosuppressant Neoral (ciclosporin) has been approved for severe atopic dermatitis exhibiting insufficient responses to current drugs...already sell Neoral for this indication. Novartis will not add severe atopic dermatitis to its other ciclosporin product, Sandimmum.
- Efalizumab for severe atopic dermatitis.(PIPELINE PREVIEWS)(Brief article)
- Magazine article from: Journal of Drugs in Dermatology Heller, Marissa May 1, 2007 700+ words
...prospective, open-label, pilot study of 10 patients with severe atopic dermatitis. Patients received an initial subcutaneous dose...the safety and efficacy of efalizumab for the treatment of severe atopic dermatitis. The study was published in the Journal of the...
- A multicentre, randomized, double-blind, controlled study of long-term...
- Magazine article from: Journal of Drugs in Dermatology September 1, 2005 700+ words
...with 0.1% Tacrolimus Ointment in Adults with Moderate to Severe Atopic Dermatitis Reitamo S, et al. British Journal of Dermatology...compared to topical corticosteroids in patients with moderate to severe atopic dermatitis. Nine hundred seventy-two patients were enrolled...
- Systemic cyclosporin is effective treatment for severe atopic dermatitis.
- Magazine article from: Archives of Disease in Childhood October 1, 2001 700+ words
Systemic cyclosporin is effective treatment for severe atopic dermatitis but the drug does not penetrate the epidermis and is therefore ineffective when applied topically. Two drugs, ascomycin...
- Pimecrolimus Cream 1% plus topical corticosteroid in patients (2-17 years of...
- Magazine article from: Journal of Drugs in Dermatology November 1, 2005 700+ words
...test the safety of pimecrolimus Cream 1% with topical corticosteroid treatment (commonly used in eczema) in patients with severe atopic dermatitis. Condition Intervention Phase Dermatitis, Atopic Pimecrolimus cream 1% Phase IV Study ID Numbers: ASM981C2439...
- Study to evaluate the safety and efficacy of Alefacept (Amevive) in subjects...
- Magazine article from: Journal of Drugs in Dermatology April 1, 2009 700+ words
...minimal spongiosis. This study will assess the safety, tolerability, and efficacy of Alefacept in patients with moderate to severe atopic dermatitis who could not be adequately controlled with topical therapies. Condition Intervention Phase Atopic Dermatitis...
- SR Pharma plc, of London, said it started a Phase II trial of SRP299 for the...
- Newspaper article from: BioWorld International November 27, 2002 700+ words
* SR Pharma plc, of London, said it started a Phase II trial of SRP299 for the treatment of moderate to severe atopic dermatitis in children aged 5 to 16. The trial, which aims to recruit 120 patients, will report in 2004. SRP299, being developed...
Source: HighBeam Research, Protopic.